drugset / Trial / NCT00230516

Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

NCT00230516

Phase 4 Completed 100 enrolled AstraZeneca
RandomizedCrossoverOpen-label

Summary

This study is intended to evaluate whether intravenous (iv) esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®

Timeline

Start
2005-09
Primary completion
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg Intravenous
Subject Lansoprazole Other / unclassified 30 mg Intravenous

Indications

No indication recorded.